![](https://endpts.com/wp-content/uploads/2021/04/Emma-Walmsley-GlaxoSmithKline-GSK-tile-Alamy-scaled.jpg)
Emma Walmsley, GSK CEO (MediaPunch Inc/Alamy)
FDA approves GSK's JAK inhibitor for rare blood cancer after three-month delay
The FDA approved a new JAK inhibitor, momelotinib, from GSK for adults with the rare bone marrow cancer myelofibrosis who also have anemia. The approval …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.